EUVIMEDEUVIMED entdecken
Open Access

Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App

Karen Lisa Smith iD, Hua-Ling Tsai, David Lim, Chenguang Wang, Raquel Nunes iD, Mary J Wilkinson, Jennifer Y Sheng iD, Rima Couzi, John Fetting, Carol Riley iD, Antonio C Wolff iD, Cesar A Santa-Maria iD und 8 weitere

JCO Oncology Practice · 2023

DOI: 10.1200/op.23.00038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2023. Verfasst von Karen Lisa Smith und 19 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Comprehensive Cancer Center, Women's Malignancies Disease Group, Johns Hopkins University School of Medicine, Baltimore, MD. Hauptthemen laut MEDLINE: Breast Neoplasms, Mobile Applications. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Treatment-associated symptoms drive early discontinuation of adjuvant endocrine therapy (ET) for breast cancer. We hypothesized that symptom monitoring with electronic patient-reported outcomes (ePROs) during adjuvant ET will enhance symptom detection, symptom management, and persistence. METHODS Eligible patients were initiating ET for stage 0-III breast cancer. Participants completed ePRO surveys via smartphone at baseline and 1, 3, 6, and 12 months. Measures included Patient-Reported Outcomes Measurement Information System Anxiety, Depression, Fatigue, and Vaginal Discomfort; plus Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items assessing joint pain, hot flashes, vaginal dryness, concentration problems, and memory problems. Scores surpassing prespecified thresholds triggered alerts, and recommended symptom management pathways were provided to clinicians. The primary objective was to evaluate feasibility, assessed by survey completion rates, with targets of >65% for the baseline survey and ≥1 follow-up survey during the first 6 months. Secondary objectives included 12-month ET discontinuation rate (target: ≤15%), describing symptoms and evaluating pathway implementation. RESULTS Among 250 participants, 73.2% completed the baseline survey and 69.6% completed ≥1 follow-up survey during the first 6 months. Thirty-one percent of participants had ≥1 symptom alert at baseline and 74% had ≥1 symptom alert during follow-up. The proportions of participants for whom pathway-concordant symptom management was documented at each time point ranged from 12.8% to 36.6%. Twenty-eight participants (11.2%) discontinued ET by 12 months. CONCLUSION Symptom monitoring with ePROs during adjuvant ET is feasible. Despite infrequent documentation of pathway-concordant symptom management after symptom alerts, ePROs were associated with favorable short-term ET persistence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMobile ApplicationsFemaleHumansFeasibility StudiesSurveys and QuestionnairesPatient Reported Outcome Measures

Autor:innen und Institutionen

  • Sidney Kimmel Comprehensive Cancer Center, Women's Malignancies Disease Group, Johns Hopkins University School of Medicine, Baltimore, MD.
  • AstraZeneca, Gaithersburg, MD.
  • Division of Biostatistics and Bioinformatics, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
  • Division of Statistics Collaborative Inc, WCG, Washington, DC.
  • Regeneron Pharmaceuticals, Tarrytown, NY.
  • Sibley Memorial Hospital, Washington, DC.

ORCID-Profile: Karen Lisa Smith, Raquel Nunes, Jennifer Y Sheng, Carol Riley, Antonio C Wolff, Cesar A Santa-Maria, Claire Snyder, Vered Stearns

Förderung

  • NCI NIH HHS

Zitieren

APA

Smith, K. L., Tsai, H. L., Lim, D., Wang, C., Nunes, R., Wilkinson, M. J., Sheng, J. Y., Couzi, R., Fetting, J., Riley, C., Wolff, A. C., Santa-Maria, C. A., Papathakis, K., Collins-Chase, L., Hilton, C., Thorner, E., Montanari, A., Ikejiani, D., Snyder, C., & Stearns, V. (2023). Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App. JCO Oncology Practice. https://doi.org/10.1200/op.23.00038

Vancouver

Smith KL, Tsai HL, Lim D, Wang C, Nunes R, Wilkinson MJ, et al. Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App. JCO Oncology Practice. 2023. doi:10.1200/op.23.00038

BibTeX
@article{Smith2023,
  author = {Smith, Karen Lisa and Tsai, Hua-Ling and Lim, David and Wang, Chenguang and Nunes, Raquel and Wilkinson, Mary J and Sheng, Jennifer Y and Couzi, Rima and Fetting, John and Riley, Carol and Wolff, Antonio C and Santa-Maria, Cesar A and Papathakis, Katie and Collins-Chase, Lauren and Hilton, Christie and Thorner, Elissa and Montanari, Amanda and Ikejiani, Dara and Snyder, Claire and Stearns, Vered},
  title = {Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App},
  journal = {JCO Oncology Practice},
  year = {2023},
  doi = {10.1200/op.23.00038}
}
Kostenlos starten →